Early childhood IgE reactivity to pathogenesis-related class 10 proteins predicts allergic rhinitis in adolescence - 11/05/15
, Christian Lupinek, MD c, Jean Bousquet, MD, PhD d, Niklas Andersson, MSc e, Sandra Pahr, MSc c, Alexandra Baar, PhD c, Anna Bergström, PhD e, Mats Holmström, MD, PhD a, b, Pär Stjärne, MD, PhD a, b, Karin C. Lødrup Carlsen, MD, PhD f, Kaj-Håkon Carlsen, MD, PhD f, Josep M. Antó, MD, PhD g, h, i, j, Rudolf Valenta, MD, PhD c, Marianne van Hage, MD, PhD k, Magnus Wickman, MD, PhD e, lon behalf of the
Mechanisms for the Development of Allergies (MeDALL) consortium
Abstract |
Background |
Component-resolved diagnosis might improve the prediction of future allergy in young children.
Objective |
We sought to investigate the association between IgE reactivity to the pathogenesis-related class 10 (PR-10) protein family and allergic rhinitis to birch pollen (ARbp) from early childhood up to age 16 years.
Method |
Questionnaire data and sera obtained at 4, 8, and 16 years of age from the Barn/Children Allergi/Allergy Milieu Stockholm Epidemiologic (BAMSE) study birth cohort were used. Sera from 764 children were analyzed for IgE reactivity to 9 PR-10 allergen proteins at the 3 time points by using an allergen chip based on ISAC technology. ARbp was defined as upper airway symptoms during birch pollen exposure.
Results |
IgE reactivity to Bet v 1 was found in 12%, 17%, and 25% of children at 4, 8, and 16 years of age. IgE reactivity of PR-10 proteins showed a hierarchic intrarelationship: Bet v 1 > Mal d 1 > Cor a 1.04 > Ara h 8 > Pru p 1 > Aln g 1 > Api g 1 > Act d 8 > Gly m 4. There was an increased risk of incidence and persistence of ARbp up to age 16 years with increasing levels of Bet v 1–specific IgE or increasing numbers of IgE-reactive PR-10 proteins at 4 years. Children with severe ARbp at age 16 years had higher levels of Bet v 1–specific IgE at age 4 years compared with children with mild symptoms.
Conclusion |
ARbp at age 16 years can be predicted by analysis of IgE reactivity to PR-10 proteins in early childhood.
Le texte complet de cet article est disponible en PDF.Key words : Allergen components, allergic rhinitis, oral allergy syndrome, BAMSE, birch pollen, cohort, cross-reactivity, IgE, MeDALL, microarray
Abbreviations used : AR, ARbp, BAMSE, ISU-E, MeDALL, OAS, OR, PR-10
Plan
| Supported by the Swedish Asthma and Allergy Research Foundation; the Frimurare Barnhuset Foundation; the Acta Oto-Laryngologica Foundation; Stockholm County Council; the Swedish Research Council of Health, Working Life and Welfare; the Swedish Research Council, Swedish Heart-Lung Foundation; the Swedish Cancer and Allergy Foundation; the European Commission's Seventh Framework 29 Program MeDALL under grant agreement no. 261357, and in part by grant F4605 of the Austrian Science Fund (FWF). |
|
| Disclosure of potential conflict of interest: C. Lupinek has received payment for delivering lectures from Thermo Fisher. J. Bousquet has received consultancy fees from Actelion, Almirall, Meda, Merck, MSD, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach, AstraZeneca, Chiesi, GlaxoSmithKline, OM Pharma, Schering Plough, and Stallergènes and received support for travel to meetings for this study or other purposes from Actelion, Almirall, Meda, Merck, MSD, Novartis, Sanofi-Aventis, Takeda, Teva, and Uriach. P. Stjärne's institution has received funding, and has received or has grants pending from the ALF. K. C. Lødrup Carlsen's institution has received funding from the EU-MeDALL (grant no. 261357). K.-H. Carlsen has received compensation for board membership from Meda and Boehringer Ingelheim, as well as consultancy fees from Novartis, and payment for delivering lectures from Takeda, Novartis, and Boehringer Ingelheim, and he has received compensation for travel and other meeting-related expenses from Sandoz. J. M. Antó's institution has received funding from the European Commission (grant no. 261357). R. Valenta's institution has received funding from the EU (grant no. 261357), he has received consultancy fees, and he has received or has grants pending from Biomay AG, Thermo Fisher Scientific, and Fresenius Medical Care. M. van Hage has received consultancy fees from Hycor Biomedical, as well as payment for delivering lectures from Thermo Fisher Scientific, Novartis, and ALK-Abelló. M. Wickman's institution has received funding from the European Union (grant no. 261357); he has received consultancy fees, payment for delivering lectures, and has received or has grants pending from Thermo Fisher Scientific; and he has also received consultancy fees from Mictrotest DX. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 135 - N° 5
P. 1199 - mai 2015 Retour au numéro
Article précédent
- The other side of asthma: Steroid-refractory disease in the absence of TH2-mediated inflammation
- Erwin W. Gelfand, Rafeul Alam
- Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy
- Margarete Focke-Tejkl, Milena Weber, Katarzyna Niespodziana, Angela Neubauer, Hans Huber, Rainer Henning, Gottfried Stegfellner, Bernhard Maderegger, Martina Hauer, Frank Stolz, Verena Niederberger, Katharina Marth, Julia Eckl-Dorna, Richard Weiss, Josef Thalhamer, Katharina Blatt, Peter Valent, Rudolf Valenta
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?